– Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down degenerative processes linked to aging and improve functional outcomes patients suffering from age-related diseases, and Skyepharma, a French pharmaceutical company specializing in the formulation, development and production of pharmaceutical products, announce the signing of a partnership for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19, with a view to requests for marketing authorizations.